<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="29eaa486-48f7-43ac-8001-bf4838738904"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use DOPAMINE HYDROCHLORIDE IN DEXTROSE INJECTION safely and effectively. See full prescribing information for DOPAMINE HYDROCHLORIDE IN DEXTROSE INJECTION. <br/>
      <br/> DOPAMINE HYDROCHLORIDE IN DEXTROSE injection, for  intravenous use <br/> Initial U.S. Approval: 1974</title>
   <effectiveTime value="20241125"/>
   <setId root="08f23f6e-150d-45ea-098e-f2edf64c21a1"/>
   <versionNumber value="23"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="141588017" root="1.3.6.1.4.1.519.1"/>
            <name>Hospira, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="093132819" root="1.3.6.1.4.1.519.1"/>
                        <name>Hospira, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-7809" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-7810" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-7809" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-7810" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-7809" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-7810" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-7809" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-7810" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="827731089" root="1.3.6.1.4.1.519.1"/>
                        <name>Hospira, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-7809" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-7810" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="f93bc420-0a11-4516-8c1b-7e3ebaeec766"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20210923"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0409-7809" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dopamine Hydrochloride in Dextrose</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Dopamine Hydrochloride in Dextrose</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="1.6"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7L3E358N9L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DOPAMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="VTD58H1Z2X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DOPAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="LX22YL083G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4VON5FNS3C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM METABISULFITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="250"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0409-7809-11" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="12"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0409-7809-22" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20050430"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="500"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0409-7809-31" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="12"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0409-7809-24" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20051014"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA018826" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20050430"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0409-7810" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dopamine Hydrochloride in Dextrose</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Dopamine Hydrochloride in Dextrose</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3.2"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7L3E358N9L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DOPAMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="VTD58H1Z2X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DOPAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="LX22YL083G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4VON5FNS3C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM METABISULFITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="250"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0409-7810-11" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="12"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0409-7810-22" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20050808"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA018826" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20050808"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="19370077-b815-4f35-9b52-4403aa040e96"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Dopamine Hydrochloride in Dextrose Injection is indicated to improve hemodynamic status in patients in distributive shock, or shock due to reduced cardiac output.</paragraph>
               </text>
               <effectiveTime value="20210923"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Dopamine HCl in Dextrose Injection is a catecholamine indicated to improve hemodynamic status in patients in shock. (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="893ce06f-2164-421a-ab2e-4423c00341b4"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20210923"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Correct hypovolemia, acidosis, and hypoxia prior to use. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Administer in a large vein with an infusion pump preferably in an intensive care setting. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Recommended starting dosage in adults and pediatric patients is 2 to 5 mcg/kg/minute as a continuous intravenous infusion. Titrate in 5 to 10 mcg/kg/minute increments based on hemodynamic response and tolerability, up to not more than 50 mcg/kg/minute. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>See the Full Prescribing Information for important preparation instructions and drug incompatibilities. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="3eef36ce-503f-4906-8365-72d0571d138c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Administration Instructions</title>
                     <effectiveTime value="20210923"/>
                     <component>
                        <section ID="ID_e45ed96d-5d47-4a7a-b273-e44210f4b3f7">
                           <id root="3d454a56-b662-42b0-801f-583c7da7f29d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Correct Hypovolemia, Acidosis, and Hypoxia</content>
                              </paragraph>
                              <paragraph>Address hypovolemia, acidosis, and hypoxia before initiating Dopamine HCl in Dextrose Injection. If patient does not respond to therapy, suspect occult hypovolemia. Acidosis may reduce the effectiveness of dopamine <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20210923"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_cd7646e3-1446-48ae-b9e3-8d9dd7169632">
                           <id root="52898e0b-a5e7-4ade-8e28-68ac55527b82"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Administration</content>
                              </paragraph>
                              <paragraph>Dopamine HCl in Dextrose Injection is a premixed infusion solution that does not require dilution prior to intravenous administration. Administer Dopamine HCl in Dextrose Injection into a large vein <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content> with the use of an infusion pump preferably in an intensive care setting.</paragraph>
                              <paragraph>Remove outer wrap (moisture and oxygen barrier) only when ready to administer the product. Discard product if outer wrap is damaged (e.g., tears or holes). Inspect Dopamine HCl in Dextrose Injection for particulate matter and discoloration prior to administration (the solution is clear to slightly yellow). Do not administer if the solution is darker than slightly yellow or the container is damaged.</paragraph>
                              <paragraph>Use higher concentration premixed solutions (e.g., 3200 mcg/mL or 1600 mcg/mL strengths) in patients requiring fluid restriction.</paragraph>
                           </text>
                           <effectiveTime value="20210923"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_de0a9e50-ae9a-43ce-ae68-4a661671d1ed">
                           <id root="db0abfa2-c17c-4b6c-aac9-37426045755d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Discontinuation</content>
                              </paragraph>
                              <paragraph>When discontinuing Dopamine HCl in Dextrose Injection, gradually reduce the infusion rate while expanding blood volume with intravenous fluids <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210923"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="0eb2c022-2303-4427-b8b5-d856af4909a1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Recommended Dosage</title>
                     <text>
                        <paragraph>The recommended starting dosage in adults and pediatric patients is 2 to 5 mcg/kg/minute as a continuous intravenous infusion <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>. Titrate the infusion rate in 5 to 10 mcg/kg/minute increments based on hemodynamic response and tolerability, up to but not more than 50 mcg/kg/minute.</paragraph>
                        <paragraph>Infusion rates may be calculated using the following formula:</paragraph>
                        <table styleCode="Noautorules" width="60%">
                           <col width="20%"/>
                           <col width="49%"/>
                           <tbody>
                              <tr>
                                 <td align="right" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Infusion Rate (mL/hour) = </content>
                                    </paragraph>
                                 </td>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">
                                          <content styleCode="underline">[Dose (mcg/kg/minute) × Weight (kg) × 60 (minutes/hour)]</content>
                                       </content>
                                       <br/>
                                       <content styleCode="bold">                            Concentration (mcg/mL)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Example calculations for infusion rates are as follows:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Example 1:</content> for a 60 kg person at the recommended initial dose of 2 mcg/kg/minute using an 800 mcg/mL concentration, the infusion rate would be as follows:</paragraph>
                        <table width="60%">
                           <col width="20%"/>
                           <col width="33%"/>
                           <col width="16%"/>
                           <tbody>
                              <tr styleCode="Toprule">
                                 <td align="right" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Infusion Rate</content> (mL/hour) <content styleCode="bold">=</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>
                                       <content styleCode="underline">
                                          <content styleCode="bold">[2</content> (mcg/kg/minute) <content styleCode="bold">× 60</content> (kg) <content styleCode="bold">× 60</content> (minutes/hour)<content styleCode="bold">]</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="2" valign="top">
                                    <paragraph>
                                       <content styleCode="bold"> = 9</content> (mL/hour)</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td valign="top"/>
                                 <td align="center" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">800</content> (mcg/mL)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">Example 2:</content> for a 70 kg person at a dose of 5 mcg/kg/minute using a 3,200 mcg/mL concentration, the infusion rate would be as follows:</paragraph>
                        <table width="60%">
                           <col width="20%"/>
                           <col width="33%"/>
                           <col width="16%"/>
                           <tbody>
                              <tr styleCode="Toprule">
                                 <td align="right" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Infusion Rate</content> (mL/hour) <content styleCode="bold">=</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" valign="top">
                                    <paragraph>
                                       <content styleCode="underline">
                                          <content styleCode="bold">[5</content> (mcg/kg/minute) <content styleCode="bold">× 70</content> (kg) <content styleCode="bold">× 60</content> (minutes/hour)<content styleCode="bold">]</content>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td rowspan="2" valign="top">
                                    <paragraph>
                                       <content styleCode="bold"> = 6.56</content> (mL/hour)</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td valign="top"/>
                                 <td align="center" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">3200</content> (mcg/mL)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20210923"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="b607b44f-4afc-4ad0-9f23-9041ef2d4c40"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Drug Incompatibilities</title>
                     <text>
                        <paragraph>Dopamine HCl in Dextrose Injection is incompatible with the following products; therefore, avoid simultaneous administration (through the same infusion set):</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Sodium bicarbonate or other alkalinizing substances, because dopamine is inactivated in alkaline solution.</item>
                           <item>
                              <caption>•</caption>Blood, because of the risk of pseudoagglutination of red cells</item>
                           <item>
                              <caption>•</caption>Iron salts</item>
                        </list>
                        <paragraph>Do not add additional medications in the premixed infusion solution.</paragraph>
                     </text>
                     <effectiveTime value="20210923"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="ebe59ae3-e989-494d-a783-a1c405558964"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>The following strengths of Dopamine Hydrochloride in 5% Dextrose Injection, USP, are supplied in LifeCare flexible single-dose plastic containers (the solutions are clear to slightly yellow in appearance):</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>800 mcg/mL (250 or 500 mL)</item>
                     <item>
                        <caption>•</caption>1600 mcg/mL (250 or 500 mL)</item>
                     <item>
                        <caption>•</caption>3200 mcg/mL (250 mL)</item>
                  </list>
                  <paragraph>Each 100 mL contains 5 grams of hydrous dextrose in Water for Injection.</paragraph>
               </text>
               <effectiveTime value="20210923"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Following strengths of Dopamine Hydrochloride in 5% Dextrose Injection, USP, are supplied in LifeCare flexible single-dose plastic containers (each 100 mL contains 5 grams of hydrous dextrose in Water for Injection): (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>800 mcg/mL (250 and 500 mL)</item>
                           <item>
                              <caption>•</caption>1600 mcg/mL (250 and 500 mL)</item>
                           <item>
                              <caption>•</caption>3200 mcg/mL (250 mL)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="6f50d728-7bb1-4d74-8d20-e27b6de4137d"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Dopamine is contraindicated in patients with pheochromocytoma.</paragraph>
               </text>
               <effectiveTime value="20210923"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Patients with pheochromocytoma. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="725c99e3-fa64-4c36-8489-d6a0a1878d5c"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20210923"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Tissue ischemia</content>: Severe peripheral and visceral vasoconstriction can occur. Address hypovolemia prior to use, monitor extremities, and infuse into large vein. (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Cardiac arrhythmias</content>: Monitor closely. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Hypotension after abrupt discontinuation</content>: Gradually reduce infusion rate while expanding blood volume with intravenous fluids. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Severe hypersensitivity reactions due to sodium metabisulfite excipient</content>: May cause anaphylaxis including life-threatening or less severe asthmatic episodes in susceptible individuals. (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="598db797-27d9-4a04-83b3-5a6cd1f9c23a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Tissue Ischemia </title>
                     <text>
                        <paragraph>Administration of dopamine to patients who are hypotensive from hypovolemia can result in severe peripheral and visceral vasoconstriction, decreased renal perfusion and hypouresis, tissue hypoxia, lactic acidosis, and poor systemic blood flow despite "normal" blood pressure. Address hypovolemia prior to initiating Dopamine HCl in Dextrose Injection <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Gangrene of the extremities has occurred in patients with occlusive vascular disease or who received prolonged or high dose infusions. Monitor for changes to the skin of the extremities in susceptible patients. </paragraph>
                        <paragraph>Extravasation of Dopamine HCl in Dextrose Injection may cause necrosis and sloughing of surrounding tissue. To reduce the risk of extravasation, infuse into a large vein <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>]</content>, check the infusion site frequently for free flow, and monitor for signs of extravasation.</paragraph>
                     </text>
                     <effectiveTime value="20210923"/>
                     <component>
                        <section ID="ID_0da67f4d-90ca-4af2-8cf7-32e1f428346c">
                           <id root="c8f7fa44-bd83-4553-a9ad-d016115bc01b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Emergency Treatment of Extravasation</content>
                              </paragraph>
                              <paragraph>To prevent sloughing and necrosis in areas in which extravasation has occurred, infiltrate the ischemic area as soon as possible, using a syringe with a fine hypodermic needle with:</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>5 to 10 mg of phentolamine mesylate in 10 to 15 mL of 0.9% Sodium Chloride Injection in adults</item>
                                 <item>
                                    <caption>•</caption>0.1 to 0.2 mg/kg of phentolamine mesylate up to a maximum of 10 mg per dose in pediatric patients.</item>
                              </list>
                              <paragraph>Sympathetic blockade with phentolamine causes immediate and conspicuous local hyperemic changes if the area is infiltrated within 12 hours.</paragraph>
                           </text>
                           <effectiveTime value="20210923"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="b16c808a-b6f3-417c-acf4-4cb8abcf5aa3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Cardiac Arrhythmias</title>
                     <text>
                        <paragraph>Dopamine may cause arrhythmias. Monitor patients with arrhythmias and treat appropriately.</paragraph>
                     </text>
                     <effectiveTime value="20210923"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="fed4a7d3-e171-4b3c-a306-5782fa199223"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Hypotension after Abrupt Discontinuation</title>
                     <text>
                        <paragraph>Sudden cessation of the infusion rate may result in marked hypotension. Gradually reduce the infusion rate while expanding blood volume with intravenous fluids.</paragraph>
                     </text>
                     <effectiveTime value="20210923"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="acb4220c-be39-4e4b-b246-89da4775c222"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Severe Hypersensitivity Reactions due to Sodium Metabisulfite Excipient</title>
                     <text>
                        <paragraph>Dopamine HCl in Dextrose Injection, contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.</paragraph>
                     </text>
                     <effectiveTime value="20210923"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="e75fdab4-7618-4e48-b933-1d6524590afb"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Tissue Ischemia <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Cardiac Arrhythmias <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hypotension <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Severe Hypersensitivity Reactions <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                  </list>
                  <paragraph>The following adverse reactions have been identified during post-approval use of dopamine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Cardiac Disorders</content>: anginal pain, palpitation<br/>
                     <content styleCode="underline">Gastrointestinal Disorders</content>: nausea, vomiting<br/>
                     <content styleCode="underline">Metabolism and Nutrition Disorders</content>: azotemia<br/>
                     <content styleCode="underline">Nervous System Disorders</content>: headache, anxiety<br/>
                     <content styleCode="underline">Respiratory Disorders</content>: dyspnea<br/>
                     <content styleCode="underline">Skin and Subcutaneous Tissue Disorders</content>: piloerection<br/>
                     <content styleCode="underline">Vascular Disorders</content>: hypertension</paragraph>
               </text>
               <effectiveTime value="20210923"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reaction is localized vasoconstriction due to extravasation. (<linkHtml href="#S6">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="2950cb06-bc62-442b-b653-48bd3d2f8541"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>See <linkHtml href="#_RefTable1">Table 1</linkHtml> for clinically significant drug interactions with dopamine.</paragraph>
                  <table ID="_RefTable1" width="75%">
                     <caption>Table 1: Clinically Significant Drug Interactions with Dopamine</caption>
                     <col width="15%"/>
                     <col width="72%"/>
                     <tbody>
                        <tr>
                           <td colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Halogenated Anesthetics</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Concomitant use may increase cardiac autonomic irritability and can sensitize the myocardium to the action of dopamine which may lead to ventricular arrhythmias and hypertension.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="italics">Intervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Monitor cardiac rhythm. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="italics">Examples:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>desflurane, enflurane, isoflurane, and sevoflurane. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">MAO Inhibitors</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine which may result in severe hypertension and cardiac arrhythmia. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="italics">Intervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Reduce the recommended starting dosage to no greater than one-tenth (1/10) of the recommended dose in patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of Dopamine HCl in Dextrose Injection.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="italics">Examples:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>isocarboxazid, phenelzine, tranylcypromine, rasagiline, selegiline, linezolid.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Tricyclic Antidepressants</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Concomitant use may potentiate the cardiovascular effects of dopamine (e.g., hypertension). </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="italics">Intervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Monitor blood pressure. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="italics">Examples:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>amitriptyline, desipramine, doxepin, imipramine, nortriptyline. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Vasopressors</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Concomitant use may result in severe hypertension. </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="italics">Intervention:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>Monitor blood pressure.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode="Rrule Botrule Lrule " valign="middle">
                              <paragraph>
                                 <content styleCode="italics">Examples:</content>
                              </paragraph>
                           </td>
                           <td styleCode="Rrule Botrule " valign="top">
                              <paragraph>norepinephrine, epinephrine, oxytocin.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20210923"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Halogenated anesthetics</content>: Can sensitize the myocardium to the effects of dopamine and can produce ventricular arrhythmias and hypertension. (<linkHtml href="#S7">7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">MAO inhibitors</content>: Risk of severe hypertension. Reduce recommended Dopamine HCl in Dextrose Injection dosage. (<linkHtml href="#S7">7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Tricyclic antidepressants</content>: Risk of hypertension. Monitor blood pressure. (<linkHtml href="#S7">7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Vasopressors</content>: Risk of severe hypertension. Monitor blood pressure. (<linkHtml href="#S7">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="8b5707e8-f141-4f89-b115-c9076cc367fa"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20210923"/>
               <component>
                  <section ID="S8.1">
                     <id root="4cd25f80-9ff8-4231-ae7b-45309c0db28b"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20210923"/>
                     <component>
                        <section ID="ID_6ce8e2ff-2401-4cf7-ae6e-df0734b9bab3">
                           <id root="e8fcfee4-aa17-41dc-ae38-ea721ecb4db0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no human data with dopamine use in pregnant women. There are risks to the mother and fetus from hypotension associated with shock, which can be fatal if left untreated (<content styleCode="italics">see <linkHtml href="#_RefCC">Clinical Considerations</linkHtml>
                                 </content>). In animal reproduction studies, adverse developmental outcomes were observed with intravenous dopamine HCl administration in pregnant rats during organogenesis at dosages, on a mcg/m<sup>2</sup> basis, of one-third the human starting dosage of 2 mcg/kg/minute (90 mcg/m<sup>2</sup>/minute).</paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies carry some risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20210923"/>
                        </section>
                     </component>
                     <component>
                        <section ID="CC">
                           <id root="beb01e11-d9f1-42bd-a1ce-b7f9f2b560b6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210923"/>
                           <component>
                              <section ID="ID_c1452276-872a-4d55-b4ae-0fd45c04cb35">
                                 <id root="001110a5-fc31-4782-aca7-33924a972f58"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Disease-associated maternal and/or embryo/fetal risk</content>
                                    </paragraph>
                                    <paragraph>Hypotension associated with distributive shock, or shock due to reduced cardiac output are medical emergencies in pregnancy which can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with distributive shock, or shock due to reduced cardiac output may increase the risk of maternal and fetal morbidity and mortality. Life-sustaining therapy for the pregnant woman should not be withheld due to potential concerns regarding the effects of dopamine on the fetus.</paragraph>
                                 </text>
                                 <effectiveTime value="20210923"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_e85d78cb-9760-4165-a12a-24dd1539091f">
                                 <id root="6dad52b2-09d5-44bd-b992-2397b463ea15"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Labor or Delivery</content>
                                    </paragraph>
                                    <paragraph>Vasopressor drugs, including dopamine, may cause severe maternal hypertension when used concomitantly with some oxytocic drugs <content styleCode="italics">[see <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]</content>. </paragraph>
                                 </text>
                                 <effectiveTime value="20210923"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_06aa6e2d-974a-423c-bb5b-44180efb11c2">
                           <id root="6c36919d-a2fa-4b8e-b0cf-80cba6a10f9b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210923"/>
                           <component>
                              <section ID="ID_3d22684f-cc42-451c-a726-6c4677cc4219">
                                 <id root="083f2ddc-8d0c-4e8c-9d8b-73dc7120039b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Animal reproduction studies in rats and rabbits at dopamine HCl dosages up to 6 mg/kg/day intravenously (on a mcg/m<sup>2</sup> basis, one-third and two-thirds, respectively, the human starting dosage of 2 mcg/kg/minute) during organogenesis produced no detectable teratogenic or embryotoxic effects, although maternal toxicity consisting of mortalities, decreased body weight gain, and pharmacotoxic signs were observed in rats. In a published study, administration of 10 mg/kg/day dopamine HCl (on a mcg/m<sup>2</sup> basis, two-thirds the human starting dosage of 2 mcg/kg/minute) to pregnant rats throughout gestation or for 5 days starting on gestation day 10 or 15 resulted in decreased body weight gain, increased mortality, and slight increase in cataract formation among the offspring. </paragraph>
                                 </text>
                                 <effectiveTime value="20210923"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="ef89c8d4-8815-4679-91a1-274be727e7f8"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20210923"/>
                     <component>
                        <section ID="ID_00a72e38-20fc-40d7-acb4-da952e000f6a">
                           <id root="8bb2b962-e7ec-4f7a-9655-c5eaa8faedaa"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data regarding the presence of dopamine in human milk, the effects of dopamine on the breastfed infant, or the effects of the drug on milk production.</paragraph>
                           </text>
                           <effectiveTime value="20210923"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="25d09bb0-e9a0-49b4-bd75-c3df2404c7bb"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Dopamine HCl infusions have been used in pediatric patients from birth through adolescence. Most reports in pediatric patients describe dosing that is similar (on a mcg/kg/minute basis) to that used in adults <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>. Except for vasoconstrictive effects caused by inadvertent infusion of dopamine into the umbilical artery, adverse reactions unique to pediatric patients have not been identified, nor have adverse reactions identified in adults been found to be more common in pediatric patients.</paragraph>
                     </text>
                     <effectiveTime value="20210923"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="aa65993b-da1c-454d-b337-90dc759e28af"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of dopamine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should start at the low end of the dosing range, reflecting the frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20210923"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="55042072-2c7e-4ed9-b557-f7ae7fdac8ed"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Manifestations of overdosage include excessive blood pressure elevation.</paragraph>
                  <paragraph>In the case of accidental overdosage, reduce rate of Dopamine HCl in Dextrose Injection infusion, or temporarily discontinue the Dopamine HCl in Dextrose Injection infusion until the overdosage related adverse reactions resolves. Since dopamine's duration of action is short, no additional remedial measures are usually necessary. If these measures fail to resolve the overdosage related adverse reactions, consider using an alpha-adrenergic blocking agent (e.g., phentolamine).</paragraph>
               </text>
               <effectiveTime value="20210923"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="7852dfd0-0009-4343-a75d-43d2c06bbdf6"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Dopamine Hydrochloride in 5% Dextrose Injection, USP is a sterile, nonpyrogenic, premixed solution of dopamine hydrochloride in 5% dextrose injection for intravenous infusion.  </paragraph>
                  <paragraph>Each 100 mL contains 80 mg (800 mcg/mL), 160 mg (1600 mcg/mL) or 320 mg (3200 mcg/mL) of dopamine HCl; 5 grams of hydrous dextrose, in Water for Injection, and 50 mg of sodium metabisulfite (a stabilizer); pH = 3.8 (2.5 to 4.5), and the following osmolar concentrations: 261, 269, or 286 mOsmol/liter, respectively. May contain hydrochloric acid and/or sodium hydroxide for pH adjustment.</paragraph>
                  <paragraph>Dopamine HCl is chemically designated 3, 4-dihydroxyphenethylamine hydrochloride (C<sub>8</sub>H<sub>11</sub>NO<sub>2</sub> ∙ HCl), a white crystalline powder freely soluble in water. Dopamine HCl has a molecular weight of 189.64 and it has the following structural formula:</paragraph>
                  <renderMultiMedia ID="id1075" referencedObject="MM1"/>
                  <paragraph>Dopamine (also referred to as 3-hydroxytyramine) is a naturally occurring endogenous catecholamine.</paragraph>
                  <paragraph>Dextrose, USP is chemically designated D-glucose monohydrate (C<sub>6</sub>H<sub>12</sub>O<sub>6</sub> ∙ H<sub>2</sub>O), a hexose sugar freely soluble in water. The molecular weight of dextrose (D-glucose) monohydrate is 198.17 and it has the following structural formula:</paragraph>
                  <renderMultiMedia ID="id1082" referencedObject="MM2"/>
                  <paragraph>Water for Injection, USP is chemically designated H<sub>2</sub>O.</paragraph>
               </text>
               <effectiveTime value="20210923"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dopamine-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dopamine-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="bb0228ab-f830-4665-a4c4-fa99073a54a8"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20210923"/>
               <component>
                  <section ID="S12.1">
                     <id root="241c75a3-f740-47d0-8b09-922d2d9adfec"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1	Mechanism of Action</title>
                     <text>
                        <paragraph>Dopamine is a natural catecholamine formed by the decarboxylation of 3,4-dihydroxyphenylalanine (DOPA). It is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system, especially in the nigrostriatal tract, and in a few peripheral sympathetic nerves.</paragraph>
                        <paragraph>Dopamine elicits its pharmacological action by activating dopamine D1 and D2 receptors, beta-1 receptors and alpha-1 receptors. The activation of different receptors leading to its effects are dependent on dopamine dose.</paragraph>
                     </text>
                     <effectiveTime value="20210923"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="8b1cd8b0-1c6a-43b6-846c-05bc2dd9f10a"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Dopamine's onset of action occurs within five minutes of intravenous administration and the duration of action is less than about ten minutes. Dopamine effects are dosage-dependent.</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>At &lt;5 mcg/kg/minute, dopamine HCl activates dopamine D1 and D2 receptors in the renal, mesenteric, and coronary vasculature causing vasodilation.</item>
                           <item>
                              <caption>•</caption>At 5 to 10 mcg/kg/minute, dopamine HCl activates beta-1 receptors enhancing heart rate and contractility.</item>
                           <item>
                              <caption>•</caption>At &gt;10 mcg/kg/minute, dopamine HCl activates alpha-1 receptors causing vasoconstriction and increased blood pressure</item>
                        </list>
                     </text>
                     <effectiveTime value="20210923"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="22992bb8-5c6d-4fb2-ad98-7f60c501913e"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20210923"/>
                     <component>
                        <section ID="ID_474b6a7b-723d-4066-bde8-cc957d79d30e">
                           <id root="8406ac8b-a157-48b1-b172-bd79a42c6401"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Following intravenous administration, dopamine is widely distributed in the body but does not cross the blood-brain barrier to a significant extent.</paragraph>
                           </text>
                           <effectiveTime value="20210923"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_fa1add36-02aa-45d0-a61a-ab7fee6d27b3">
                           <id root="19db8337-88b8-4f5b-b73e-932521d3d71f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The half-life of dopamine in adults is less than 2 minutes.</paragraph>
                           </text>
                           <effectiveTime value="20210923"/>
                           <component>
                              <section ID="ID_f4b71bb5-ed5d-4926-93d1-486ebe824d92">
                                 <id root="4651ef1d-81a9-4108-b700-630f56bd15c9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>About 75% of dopamine is metabolized by monoamine oxidase (MAO) and catechol O-methyl transferase (COMT) in the liver, kidney, and plasma to the inactive compounds homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid, and about 25% is metabolized to norepinephrine in the adrenergic nerve terminals.</paragraph>
                                 </text>
                                 <effectiveTime value="20210923"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_f8635034-9055-45be-91de-aad5e93d8eed">
                                 <id root="3ee2a84f-076f-4205-913c-d19e7c059266"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>About 80% of dopamine is renally excreted as inactive metabolites within 24 hours. Dopamine is stored in vesicles or diffused back into the plasma.</paragraph>
                                 </text>
                                 <effectiveTime value="20210923"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_0f710e71-bd2f-49d6-9680-77f3881f8842">
                           <id root="b82cdbb3-5c1e-46e2-95f0-acf4bb36644d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20210923"/>
                           <component>
                              <section ID="ID_187f5ec3-a8b6-4704-8fd0-3e743b4e53b5">
                                 <id root="800d0ae2-eef5-4407-b57d-ec40ab9db5a8"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric Patients</content>
                                    </paragraph>
                                    <paragraph>The reported clearance rate of dopamine in critically ill infants and pediatric patients ranged from 46 to 168 mL/kg/minute, with the higher values seen in the younger patients. The reported apparent volume of distribution in neonates was 0.6 to 4 L/kg, leading to an elimination half-life of 5 to 11 minutes.</paragraph>
                                 </text>
                                 <effectiveTime value="20210923"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="5575e172-1b27-4bef-a0d8-233482d822c1"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20210923"/>
               <component>
                  <section ID="S13.1">
                     <id root="6702456a-3e6c-4b99-9e83-627da93e2171"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20210923"/>
                     <component>
                        <section ID="ID_a0480a6a-cb6e-4efb-902f-785fd81e96c3">
                           <id root="17464f63-ef15-4b41-9b65-2de9435e3f06"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Long term animal studies have not been performed to evaluate the carcinogenic potential of dopamine.</paragraph>
                           </text>
                           <effectiveTime value="20210923"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_81608731-dd63-43a2-81af-8eae371c9c7d">
                           <id root="ffe7be0e-2b72-43a4-a562-a6303717324f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Dopamine HCl at doses approaching maximal solubility showed no clear genotoxic potential in the Ames test. Although there was a reproducible dose-dependent increase in the number of revertant colonies with strains TA100 and TA98, both with and without metabolic activation, the small increase was considered inconclusive evidence of mutagenicity. In the L5178Y TK<sup>+/-</sup> mouse lymphoma assay, dopamine HCl at the highest concentrations used of 750 mcg/mL without metabolic activation, and 3000 mcg/mL with activation, was toxic and associated with increases in mutant frequencies when compared to untreated and solvent controls; at the lower concentrations no increases over controls were noted.</paragraph>
                              <paragraph>No clear evidence of clastogenic potential was reported in the <content styleCode="italics">in vivo</content> mouse or male rat bone marrow micronucleus test when the animals were treated intravenously with up to 224 mg/kg and 30 mg/kg of dopamine HCl, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20210923"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="414aeb47-45cf-4a6d-8ad6-ea1300521216"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Dopamine Hydrochloride in 5% Dextrose Injection, USP, is supplied in 250 and 500 mL LifeCare flexible single-dose plastic containers (the solutions are clear to slightly yellow in appearance) as follows. Each 100 mL contains 5 grams of hydrous dextrose in Water for Injection.</paragraph>
                  <table width="90%">
                     <col width="50%"/>
                     <col width="50%"/>
                     <thead>
                        <tr>
                           <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <content styleCode="bold">Unit of Sale</content>
                           </th>
                           <th align="center" styleCode="Rrule Botrule Toprule " valign="top">
                              <content styleCode="bold">Total Strength/Total Volume</content>
                              <br/>
                              <content styleCode="bold">(Concentration)</content>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">NDC 0409-7809-22</content>
                                 <br/>12 in a case</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                              <paragraph>400 mg/250 mL<br/>(1600 mcg/mL)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">NDC 0409-7809-24</content>
                                 <br/>12 in a case</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>800 mg/500 mL<br/>(1600 mcg/mL)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">NDC 0409-7810-22</content>
                                 <br/>12 in a case</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule " valign="top">
                              <paragraph>800 mg/250 mL<br/>(3200 mcg/mL)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20210923"/>
               <component>
                  <section ID="ID_114ed924-e103-447b-84ff-525740fdac73">
                     <id root="9bddabc5-8531-4dac-b446-7b93f1e88f10"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. Discard unused portion.</paragraph>
                     </text>
                     <effectiveTime value="20210923"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="827d5a8d-2eda-49c7-a498-8721f4e44d4a"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20210923"/>
               <component>
                  <section ID="ID_aed5660f-53a2-4ff8-a789-be665b1c2c39">
                     <id root="557cbf2f-0fee-489f-92bf-a9697650204c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk of Tissue Damage</content>
                        </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption> </caption>	Advise the patient, family, or caregiver to report signs of extravasation urgently <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20210923"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_028443ca-8bab-430a-a646-09f36bfc91e1">
                     <id root="689aa5d2-b6ec-43ad-8cc6-44b8886106ec"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Cardiac Arrhythmias</content>
                        </paragraph>
                        <paragraph>Advise the patient, family, or caregiver that Dopamine HCl in Dextrose Injection can induce or worsen arrhythmias <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20210923"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a61d2325-95e6-436a-8922-f09fc34923c7">
               <id root="651f83e3-c790-4a11-8652-98ff5d599c88"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Distributed by Hospira, Inc., Lake Forest, IL 60045 USA </paragraph>
                  <renderMultiMedia ID="id1307" referencedObject="MM3"/>
                  <paragraph>LAB 1153 3.0</paragraph>
               </text>
               <effectiveTime value="20210923"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dopamine-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e1cba472-b8fc-4899-94bc-a58016e310cd">
               <id root="328adbcc-f00b-4961-9570-e5cf3d483487"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - WR-1540</title>
               <text>
                  <paragraph>TO OPEN — TEAR AT NOTCH</paragraph>
                  <paragraph>Each 100 mL contains dopamine hydrochloride 160 mg; dextrose, <br/>hydrous 5 g in water for injection; sodium metabisulfite added 50 mg.<br/> May contain hydrochloric acid and/or sodium hydroxide for pH <br/>adjustment. <br/>269 mOsmol/liter (calc.)<br/> ph 3.8 (2.5 to 4.5).</paragraph>
                  <paragraph>Single-dose container. Discard unused portion. For intravenous use. <br/>Usual dosage: see insert. WARNING: CONTAINS SULFITES.</paragraph>
                  <paragraph>Drug additives should not be made to this solution. The overwrap is a <br/>moisture and oxygen barrier. Do not remove unit from overwrap until <br/>ready for use. Visually inspect overwrap for tears or holes. Discard <br/>unit if overwrap is damaged or if solution is darker than slightly yellow<br/> or discolored in any other way. Use unit promptly when overwrap is <br/>opened. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room<br/> Temperature.] Protect from freezing. See insert. After removing the <br/>overwrap, check for minute leaks by squeezing container firmly. If<br/> leaks are found, discard solution as sterility may be impaired.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>250 mL <br/>NDC 0409-7809-11</paragraph>
                  <paragraph>DOPAMINE HCl<br/> in 5% Dextrose Injection, USP</paragraph>
                  <paragraph>400 mg/250 mL<br/> (1,600 mcg/mL)</paragraph>
                  <paragraph>Single-dose container</paragraph>
                  <paragraph>F WR-1540</paragraph>
                  <paragraph>Distributed by <br/>Hospira, Inc., Lake Forest, IL 60045 USA</paragraph>
                  <paragraph>Hospira</paragraph>
                  <renderMultiMedia ID="id1353" referencedObject="MM4"/>
               </text>
               <effectiveTime value="20210923"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - WR-1540</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dopamine-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_61db9563-1661-44d9-8464-eb015daf1980">
               <id root="c8f4de3e-fe17-4d99-8208-385cf1ac32d3"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - IM-4355</title>
               <text>
                  <paragraph>250 mL <br/>NDC 0409-7809-11</paragraph>
                  <paragraph>DOPAMINE HCl<br/>in 5% Dextrose Injection, USP</paragraph>
                  <paragraph>400 mg/250 mL<br/> (1,600  mcg/mL)</paragraph>
                  <paragraph>EACH 100 mL CONTAINS<br/> DOPAMINE HYDROCHLORIDE<br/> 160 mg; DEXTROSE, HYDROUS 5 g IN<br/> WATER FOR INJECTION; SODIUM<br/> METABISULFITE  ADDED 50 mg. MAY <br/>CONTAIN HYDROCHLORIC ACID <br/>AND/OR SODIUM HYDROXIDE FOR<br/> pH ADJUSTMENT. <br/>269 mOsmol/LITER  (CALC.) pH 3.8 <br/>(2.5 to 4.5). SINGLE-DOSE <br/>CONTAINER. DISCARD UNUSED<br/> PORTION. FOR INTRAVENOUS<br/> USE. USUAL DOSAGE: SEE INSERT. <br/>WARNING: CONTAINS SULFITES.</paragraph>
                  <paragraph>DRUG ADDITIVES SHOULD NOT <br/>BE MADE TO THIS SOLUTION.</paragraph>
                  <paragraph>STERILE NONPYROGENIC. <br/>USE ONLY IF SOLUTION IS CLEAR <br/>AND CONTAINER IS UNDAMAGED. <br/>MUST NOT BE USED IN SERIES <br/>CONNECTIONS.</paragraph>
                  <paragraph>Rx ONLY</paragraph>
                  <paragraph>7<br/> OTHER</paragraph>
                  <paragraph>Hospira</paragraph>
                  <paragraph>IM-4355</paragraph>
                  <paragraph>DISTRIBUTED BY HOSPIRA, INC., LAKE FOREST, IL 60045 USA</paragraph>
                  <renderMultiMedia ID="id1400" referencedObject="MM5"/>
               </text>
               <effectiveTime value="20210923"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - IM-4355</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dopamine-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a336ba57-4c3d-4eca-9ae6-1f324172e5c8">
               <id root="8b46e73a-d043-4bbd-91e5-00041896bd0f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 500 mL Bag Label - WR-1543</title>
               <text>
                  <paragraph>TO OPEN — TEAR AT NOTCH</paragraph>
                  <paragraph>Each 100 mL contains dopamine hydrochloride 160 mg; dextrose, <br/>hydrous 5 g in water for injection; sodium metabisulfite added 50 mg.<br/> May contain hydrochloric acid and/or sodium hydroxide for pH <br/>adjustment. <br/>269 mOsmol/liter (calc.)<br/> ph 3.8 (2.5 to 4.5).</paragraph>
                  <paragraph>Single-dose container. Discard unused portion. For intravenous use. <br/>Usual dosage: see insert. WARNING: CONTAINS SULFITES.</paragraph>
                  <paragraph>Drug additives should not be made to this solution. The overwrap is a <br/>moisture and oxygen barrier. Do not remove unit from overwrap until <br/>ready for use. Visually inspect overwrap for tears or holes. Discard <br/>unit if overwrap is damaged or if solution is darker than slightly yellow<br/> or discolored in any other way. Use unit promptly when overwrap is <br/>opened. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room<br/> Temperature.] Protect from freezing. See insert. After removing the <br/>overwrap, check for minute leaks by squeezing container firmly. If<br/> leaks are found, discard solution as sterility may be impaired.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>500 mL <br/>NDC 0409-7809-31</paragraph>
                  <paragraph>DOPAMINE HCl<br/> in 5% Dextrose Injection, USP</paragraph>
                  <paragraph>800 mg/500 mL<br/> (1,600 mcg/mL)</paragraph>
                  <paragraph>Single-dose container</paragraph>
                  <paragraph>F WR-1543</paragraph>
                  <paragraph>Distributed by <br/>Hospira, Inc., Lake Forest, IL 60045 USA</paragraph>
                  <paragraph>Hospira</paragraph>
                  <renderMultiMedia ID="id1444" referencedObject="MM6"/>
               </text>
               <effectiveTime value="20210923"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>PRINCIPAL DISPLAY PANEL - 500 mL Bag Label - WR-1543</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dopamine-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e9ec50bd-2b23-487a-b35b-df516f3767f4">
               <id root="59557719-343c-4467-b113-2f85b4cedb6b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 500 mL Bag Label - IM-4356</title>
               <text>
                  <paragraph>500 mL <br/>NDC 0409-7809-31</paragraph>
                  <paragraph>DOPAMINE HCl<br/>in 5% Dextrose Injection, USP</paragraph>
                  <paragraph>800 mg/500 mL<br/> (1,600 mcg/mL)</paragraph>
                  <paragraph>EACH 100 mL CONTAINS DOPAMINE<br/> HYDROCHLORIDE 160 mg; DEXTROSE,<br/> HYDROUS 5 g IN WATER FOR INJECTION; <br/>SODIUM METABISULFITE  ADDED 50 mg.<br/> MAY CONTAIN HYDROCHLORIC ACID <br/>AND/OR SODIUM HYDROXIDE FOR pH<br/> ADJUSTMENT.<br/> 269 mOsmol/LITER (CALC.) pH 3.8 (2.5 to<br/> 4.5). SINGLE-DOSE CONTAINER. DISCARD<br/> UNUSED PORTION. FOR INTRAVENOUS <br/>USE. USUAL DOSAGE: SEE INSERT. <br/>WARNING: CONTAINS SULFITES.</paragraph>
                  <paragraph>DRUG ADDITIVES SHOULD NOT <br/>BE MADE TO THIS SOLUTION.</paragraph>
                  <paragraph>STERILE NONPYROGENIC. <br/>USE ONLY IF SOLUTION IS CLEAR AND<br/> CONTAINER IS UNDAMAGED.  MUST NOT<br/> BE USED IN SERIES CONNECTIONS.</paragraph>
                  <paragraph>Rx ONLY</paragraph>
                  <paragraph>7<br/> OTHER</paragraph>
                  <paragraph>Hospira</paragraph>
                  <paragraph>IM-4356</paragraph>
                  <paragraph>DISTRIBUTED BY HOSPIRA, INC., LAKE FOREST, IL 60045 USA</paragraph>
                  <renderMultiMedia ID="id1488" referencedObject="MM7"/>
               </text>
               <effectiveTime value="20210923"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>PRINCIPAL DISPLAY PANEL - 500 mL Bag Label - IM-4356</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dopamine-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_c3698727-2861-430c-8897-6395a5519e8d">
               <id root="5f3ae2ef-af6b-4524-bdcd-baf6a9e005b6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - WR-1544</title>
               <text>
                  <paragraph>TO OPEN — TEAR AT NOTCH</paragraph>
                  <paragraph>Each 100 mL contains dopamine hydrochloride 320 mg; dextrose, <br/>hydrous 5 g in water for injection; sodium metabisulfite added 50 mg.<br/> May contain hydrochloric acid and/or sodium hydroxide for pH <br/>adjustment. <br/>286 mOsmol/liter (calc.)<br/> ph 3.8 (2.5 to 4.5).</paragraph>
                  <paragraph>Single-dose container. Discard unused portion. For intravenous use. <br/>Usual dosage: see insert. WARNING: CONTAINS SULFITES.</paragraph>
                  <paragraph>Drug additives should not be made to this solution. The overwrap is a <br/>moisture and oxygen barrier. Do not remove unit from overwrap until <br/>ready for use. Visually inspect overwrap for tears or holes. Discard <br/>unit if overwrap is damaged or if solution is darker than slightly yellow<br/> or discolored in any other way. Use unit promptly when overwrap is <br/>opened. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room<br/> Temperature.] Protect from freezing. See insert. After removing the <br/>overwrap, check for minute leaks by squeezing container firmly. If<br/> leaks are found, discard solution as sterility may be impaired.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>250 mL <br/>NDC 0409-7810-11</paragraph>
                  <paragraph>DOPAMINE HCl<br/> in 5% Dextrose Injection, USP</paragraph>
                  <paragraph>800 mg/250 mL<br/> (3,200 mcg/mL)</paragraph>
                  <paragraph>Single-dose container</paragraph>
                  <paragraph>F WR-1544</paragraph>
                  <paragraph>Distributed by <br/>Hospira, Inc., Lake Forest, IL 60045 USA</paragraph>
                  <paragraph>Hospira</paragraph>
                  <renderMultiMedia ID="id1532" referencedObject="MM8"/>
               </text>
               <effectiveTime value="20210923"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - WR-1544</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dopamine-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f5493cf4-77af-4549-b4e1-b6b23d3c7df8">
               <id root="b5956b37-b9ab-4072-a68c-7bff32377e95"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - IM-4357</title>
               <text>
                  <paragraph>250 mL <br/>NDC 0409-7810-11</paragraph>
                  <paragraph>DOPAMINE HCl<br/>in 5% Dextrose Injection, USP</paragraph>
                  <paragraph>800 mg/250 mL<br/> (3,200 mcg/mL)</paragraph>
                  <paragraph>EACH 100 mL CONTAINS DOPAMINE<br/> HYDROCHLORIDE 320 mg; DEXTROSE,<br/> HYDROUS 5 g IN WATER FOR <br/>INJECTION; SODIUM METABISULFITE<br/> ADDED 50 mg. MAY CONTAIN<br/> HYDROCHLORIC ACID AND/OR<br/> SODIUM HYDROXIDE FOR pH<br/> ADJUSTMENT. 286 mOsmol/LITER<br/> (CALC.) pH 3.8 (2.5 to 4.5). SINGLE-<br/>DOSE CONTAINER. DISCARD UNUSED<br/> PORTION. FOR INTRAVENOUS USE. <br/>USUAL DOSAGE: SEE INSERT. <br/>WARNING: CONTAINS SULFITES.</paragraph>
                  <paragraph>DRUG ADDITIVES SHOULD NOT <br/>BE MADE TO THIS SOLUTION.</paragraph>
                  <paragraph>STERILE NONPYROGENIC. <br/>USE ONLY IF SOLUTION IS CLEAR <br/>AND CONTAINER IS UNDAMAGED. <br/>MUST NOT BE USED IN SERIES <br/>CONNECTIONS.</paragraph>
                  <paragraph>Rx ONLY</paragraph>
                  <paragraph>7<br/> OTHER</paragraph>
                  <paragraph>IM-4357</paragraph>
                  <paragraph>Hospira</paragraph>
                  <paragraph>DISTRIBUTED BY HOSPIRA, INC., LAKE FOREST, IL 60045 USA</paragraph>
                  <renderMultiMedia ID="id1578" referencedObject="MM9"/>
               </text>
               <effectiveTime value="20210923"/>
               <component>
                  <observationMedia ID="MM9">
                     <text>PRINCIPAL DISPLAY PANEL - 250 mL Bag Label - IM-4357</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dopamine-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>